Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease
Inflammation and Regeneration · 19.07.2024 · 44 (1)
DOI: 10.1186/s41232-024-00345-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammation and Regeneration, online erschienen am 19.07.2024. Verfasst von Yasuhiko Nishioka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tokushima University, Tokushima, Japan. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nippon Boehringer Ingelheim.
Abstract (Originalsprache)
Background
Interstitial lung diseases (ILDs) are a diverse group of conditions characterized by inflammation and fibrosis in the lung. In some patients with ILD, a progressive fibrotic phenotype develops, which is associated with an irreversible decline in lung function and a poor prognosis. Main body The pathological mechanisms that underlie this process culminate in fibroblast activation, proliferation, and differentiation into myofibroblasts, which deposit extracellular matrix proteins and result in fibrosis. Upstream of fibroblast activation, epithelial cell injury and immune activation are known initiators of fibrosis progression, with multiple diverse cell types involved. Recent years have seen an increase in our understanding of the complex and interrelated processes that drive fibrosis progression in ILD, in part due to the advent of single-cell RNA sequencing technology and integrative multiomics analyses. Novel pathological mechanisms have been identified, which represent new targets for drugs currently in clinical development. These include phosphodiesterase 4 inhibitors and other molecules that act on intracellular cyclic adenosine monophosphate signaling, as well as inhibitors of the autotaxin-lysophosphatidic acid axis and $$\alpha_v$$ α v integrins. Here, we review current knowledge and recent developments regarding the pathological mechanisms that underlie progressive fibrotic ILD, including potential therapeutic targets.
Conclusion
Knowledge of the pathological mechanisms that drive progressive fibrosis in patients with ILD has expanded, with the role of alveolar endothelial cells, the immune system, and fibroblasts better elucidated. Drugs that target novel mechanisms hold promise for expanding the future therapeutic armamentarium for progressive fibrotic ILD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tokushima University, Tokushima, Japan.
- The Jikei University School of Medicine, Tokyo, Japan.
- University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. kumanogo@imed3.med.osaka-u.ac.jp.
Förderung
- Nippon Boehringer Ingelheim
Zitieren
APA
Nishioka, Y., Araya, J., Tanaka, Y., & Kumanogoh, A. (2024). Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease. Inflammation and Regeneration, 44(1). https://doi.org/10.1186/s41232-024-00345-2
Vancouver
Nishioka Y, Araya J, Tanaka Y, Kumanogoh A. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease. Inflammation and Regeneration. 2024;44(1). doi:10.1186/s41232-024-00345-2
BibTeX
@article{Nishioka2024,
author = {Nishioka, Yasuhiko and Araya, Jun and Tanaka, Yoshiya and Kumanogoh, Atsushi},
title = {Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease},
journal = {Inflammation and Regeneration},
year = {2024},
volume = {44},
number = {1},
doi = {10.1186/s41232-024-00345-2}
}
EUVIMED